Skip to content

The Value of FeNO in Predicting Airway Eosinophilic Inflammation

The Value of Exhaled Nitric Oxide in Predicting Airway Eosinophilic Inflammation in Chronic Airway Inflammatory Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04885738
Acronym
FeNO-Eos
Enrollment
2052
Registered
2021-05-13
Start date
2021-05-25
Completion date
2022-05-30
Last updated
2021-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway Inflammation, Biomarkers

Brief summary

To investigate and compare the value of FeNO, blood Eos, serum TIgE in predicting the airway eosinophilic inflammationin chronic cough, asthma and COPD.

Detailed description

Cough is the most common complaint in the respiratory department, while asthma and chronic obstructive pulmonary disease(COPD) are two major respiratory disease that seriously endanger human health. The common test to identify the cause and evaluate the therapeutic effect such as induced sputum, pulmonary ventilation function test, bronchial provocation test, etc. are time-consuming and laborious. There is an urgent need for an easily detectable index in the clinic to quickly identify airway eosinophilic inflammation in chronic cough, asthma and COPD, which will provide important guidance for clinical treatment. As a new marker of airway inflammation, exhaled nitric oxide(FeNO) can reflect eosinophilic airway inflammation. Mean while, FeNO has the advantages of non-invasive, simple operation, time-saving, labor-saving, and good reproducibility, which is suitable for clinical application. This prospective, multi-center study aims to explore the value of FeNO in predicting airway eosinophilic inflammation and compare it with blood Eos and TLgE in patients with chronic cough, asthma and COPD.

Interventions

OTHERno intervention

For Chronic Cough,follow《Guidelines for the diagnosis and treatment of cough》(2015). For Asthma, follow GINA For COPD, follow GOLD.

Sponsors

Nanfang Hospital, Southern Medical University
CollaboratorOTHER
Guangdong Provincial Hospital of Traditional Chinese Medicine
CollaboratorOTHER
Huizhou Third People's Hospital
CollaboratorUNKNOWN
Tongji Hospital
CollaboratorOTHER
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
CollaboratorOTHER
Ruijin Hospital
CollaboratorOTHER
First Hospital of China Medical University
CollaboratorOTHER
The First Affiliated Hospital of Shanxi Medical University
CollaboratorOTHER
Henan Provincial People's Hospital
CollaboratorOTHER
The Second Hospital of Hebei Medical University
CollaboratorOTHER
West China Hospital
CollaboratorOTHER
The First People's Hospital of Yunnan
CollaboratorOTHER
Inner Mongolia People's Hospital
CollaboratorOTHER
Second Hospital of Jilin University
CollaboratorOTHER
The First Affiliated Hospital of Guangzhou Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Candidates voluntarily participate in and abide by the relevant regulations of the study, can cooperate with corresponding inspections, follow the follow-up plan, and voluntarily sign written informed consent. * Patients with chronic cough 1. Coughing lasting ≥ 8 weeks, 2. There is no obvious abnormality in the chest X-ray 3. No clear history of upper respiratory tract infection in the past 4 weeks, 4. Newly diagnosed or untreated in the last 4 weeks 5. Non-smokers. * Patients with Asthma 1. For newly diagnosed and previously diagnosed asthma patients, the diagnosis criteria for asthma: 2. Including various disease severity (mild, moderate, severe), various disease states (chronic duration, acute exacerbation period). 3. Non-smokers. * Patients with COPD 1) Including patients in stable phase and acute exacerbation phase.

Exclusion criteria

* Diagnose patients with ACO; * Those who cannot cooperate with the completion of research-related test, follow-ups and other reasons cannot cooperate with the progress of the research; * Combined with serious diseases of other systems (such as cardiovascular, metabolic, immune, neurological, etc.). With other diseases of the lung, including bronchiectasis.

Design outcomes

Primary

MeasureTime frameDescription
predictive value of FeNO in eosinophilic airway inflammation12 monthspredictive value of FeNO in eosinophilic airway inflammation in patients with chronic cough, classic asthma, COPD
predictive value of blood eosinophils in eosinophilic airway inflammation12 monthspredictive value of blood eosinophils in eosinophilic airway inflammation in patients with chronic cough, classic asthma, COPD
predictive value of TIgE in eosinophilic airway inflammation12 monthspredictive value of TIgE in eosinophilic airway inflammation in patients with chronic cough, classic asthma, COPD

Secondary

MeasureTime frameDescription
comparison of FeNO, blood eosinophils, TIgE in predicting eosinophilic airway inflammation12 monthscomparison the predictive value of FeNO, blood eosinophils, TIgE in eosinophilic airway inflammation in patients with chronic cough, classic asthma, COPD respectively
combination of biomarkers in predicting eosinophilic airway inflammation12 monthscombination of FeNO, blood eosinophils, TIgE in predicting eosinophilic airway inflammation in patients with chronic cough, classic asthma and COPD respectively

Other

MeasureTime frameDescription
correlation12 monthscorrelation between FeNO and sputum eosinophils before and after the treatment in patients with chronic cough, asthma

Countries

China

Contacts

Primary ContactKefang Lai, phD
klai@163.com0086+020-8306-2891

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026